An error has occurred while submitting. Please try again later...
Your form was submitted successfully
Early initiation of Veraflo Therapy can potentially improve clinical outcomes
and reduce costs versus standard of care.
Can the timing of 3M™ Veraflo™ Therapy initiation help impact outcomes?
Delayed healing and wound complications are significant care and cost burdens. Wound complications and their associated costs can increase when treatment is delayed. A retrospective analysis of a national, all-payer hospital database of 514 patients (257 per group)¹ who received Veraflo Therapy in 2019 suggests that early use of Veraflo Therapy (within 1 day of NPWT application) compared to late initiation of Veraflo Therapy (within 2-7 days) can help improve clinical outcomes and reduce the cost of care.
Patients with Day 1 initiation of Veraflo Therapy reported:
4.4 days shorter average duration of the NPTW therapy (7.0 vs 11.4¹)
2.9 days shorter inpatient stay (13.4 vs. 16.3 p<0.0001¹)
Fewer wound-related readmissions at 30 days (6 vs 16; p=0.0293) and 60 days (10 vs 24; p=0.0130¹)
Veraflo Therapy combines the benefits of V.A.C.® Therapy with an instillation therapy option that features automated volumetric delivery of topical wound cleansing solutions and a programmable soak feature, which allows the solution to dwell in the wound for thorough contact.
Delivers topical wound solutions that dwell in the wound to help dilute and solubilise infectious material².
Removes solubilised wound debris and infectious materials under negative pressure to manage bioburden³.
Promotes granulation tissue formation and perfusion to prepare the wound for closure⁴.
A systematic review of comparative studies and meta-analysis⁵ evaluated the performance of Veraflo Therapy versus control in 13 studies and 720 patients with various wound types. Results of the analysis revealed Veraflo Therapy delivered significant advantages over standard of care.
>30% fewer surgical debridements⁵,⁶
(1.77 debridements vs 2.69, p=0.008)
Wounds were 2.39 times more likely to close⁵,⁶
(p=0.01)
>50% reduced length of therapy⁵,⁶
9.88 days vs 21.8 days, p=0.02)
Reduced bacterial count from baseline⁵
(Odds were 4.4 times greater p=0.003)
Based upon the meta-analysis by Allen Gabriel, MD et al. an economic model⁵ was developed to compare the cost of using Veraflo Therapy to traditional wound care options, including 3M™ V.A.C.® Therapy. Despite the higher therapy cost of Veraflo Therapy, the reduction in therapy time and required OR visits resulted in a potential savings of 50%, or up to $33,338 per patient⁷.
Find application videos, clinical compendiums, case studies and more in our resource library.
1. Collinsworth AW, Griffin LP. The effect of timing of instillation therapy on outcomes and costs for patients receiving negative pressure wound therapy. Wounds. 2022;34(11):269-275. doi:10.25270/wnds/22013
2. Teot L, Boissiere F, Fluieraru S. Novel foam dressing using negative pressure wound therapy with instillation to remove thick exudate. Int Wound J. 2017;14(5):842-848.
3. Brinkert D, Mazen A, Naud M, Maire N, Trial C, Teot L. Negative pressure wound therapy with saline instillation: 131 patient case series. Int Wound J. 2013;10 Suppl 1:56-60
4. Gupta S, Gabriel A, Lantis J, Teot L. Clinical recommendations and practical guide for negative pressure wound therapy with instillation. Int Wound J. 2016;13(2):159-174.
5. Gabriel A, Camardo M, O' Rorke E, Gold R, Kim PJ. Effects of Negative-Pressure Wound Therapy With Instillation versus Standard of Care in Multiple Wound Types: Systematic Literature Review and Meta-Analysis. Plastic and Reconstructive Surgery. 2021; 147; 1S-1.
6. Camardo, Mark. “Veraflo Meta-Analysis Standardized and Non-Standardized Means.”, 3M Internal Report, San Antonio, Texas, 2020.
7. Kim PJ, Lookess S, Bongards C, Griffin LP, Gabriel A. Economic model to estimate cost of negative pressure wound therapy with instillation vs control therapies for hospitalised patients in the United States, Germany, and United Kingdom. Int Wound J. 2021;1–7
KCI Medical Australia Pty Ltd, Level 3, Building A, 1 Rivett Road, North Ryde NSW 2113
Ph: 1300 524 822